574 related articles for article (PubMed ID: 3088026)
41. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
42. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
[TBL] [Abstract][Full Text] [Related]
43. The control on growth hormone release by free fatty acids is maintained in acromegaly.
Lanzi R; Losa M; Mignogna G; Caumo A; Pontiroli AE
J Clin Endocrinol Metab; 1999 Apr; 84(4):1234-8. PubMed ID: 10199760
[TBL] [Abstract][Full Text] [Related]
44. Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects.
Valcavi R; Zini M
Clin Endocrinol (Oxf); 1994 Mar; 40(3):379-82. PubMed ID: 8187302
[TBL] [Abstract][Full Text] [Related]
45. Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.
Vance ML; Kaiser DL; Rivier J; Vale W; Thorner MO
J Clin Endocrinol Metab; 1986 Mar; 62(3):591-4. PubMed ID: 3080467
[TBL] [Abstract][Full Text] [Related]
46. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
[TBL] [Abstract][Full Text] [Related]
47. A re-evaluation of the prolactin-releasing activity of growth hormone-releasing hormone in acromegaly in vivo.
Watanobe H; Tamura T
Neuropeptides; 1995 Feb; 28(2):73-8. PubMed ID: 7746357
[TBL] [Abstract][Full Text] [Related]
48. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
[TBL] [Abstract][Full Text] [Related]
49. Effects of pulsatile administration of growth hormone (GH)-releasing hormone on short term linear growth in children with GH deficiency.
Gelato MC; Ross JL; Malozowski S; Pescovitz OH; Skerda M; Cassorla F; Loriaux DL; Merriam GR
J Clin Endocrinol Metab; 1985 Sep; 61(3):444-50. PubMed ID: 3926806
[TBL] [Abstract][Full Text] [Related]
50. Increased growth hormone pulse frequency in acromegaly.
Barkan AL; Stred SE; Reno K; Markovs M; Hopwood NJ; Kelch RP; Beitins IZ
J Clin Endocrinol Metab; 1989 Dec; 69(6):1225-33. PubMed ID: 2511221
[TBL] [Abstract][Full Text] [Related]
51. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in acromegaly and type I diabetes mellitus.
Pietschmann P; Schernthaner G; Luger A
J Clin Endocrinol Metab; 1986 Aug; 63(2):389-93. PubMed ID: 3088023
[TBL] [Abstract][Full Text] [Related]
52. Galanin infusion partially restores the blunted growth hormone responses to repeated growth hormone releasing hormone stimuli in normal adults.
Sartorio A; Spada A; Conti A; Grugni G; Morabito F; Faglia G
J Endocrinol Invest; 1993 Feb; 16(2):95-8. PubMed ID: 7681861
[TBL] [Abstract][Full Text] [Related]
53. Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects.
Losa M; Schopohl J; Müller OA; von Werder K
Acta Endocrinol (Copenh); 1985 Aug; 109(4):467-73. PubMed ID: 3929513
[TBL] [Abstract][Full Text] [Related]
54. Acromegaly due to ectopic growth hormone (GH)-releasing hormone (GHRH) production: dynamic studies of GH and ectopic GHRH secretion.
Barkan AL; Shenker Y; Grekin RJ; Vale WW; Lloyd RV; Beals TF
J Clin Endocrinol Metab; 1986 Nov; 63(5):1057-64. PubMed ID: 3093517
[TBL] [Abstract][Full Text] [Related]
55. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
[TBL] [Abstract][Full Text] [Related]
56. Secretion of growth hormone-releasing hormone in patients with idiopathic pituitary dwarfism and acromegaly.
Yamasaki R; Saito H; Kameyama K; Hosoi E; Saito S
Acta Endocrinol (Copenh); 1988 Mar; 117(3):273-81. PubMed ID: 2898191
[TBL] [Abstract][Full Text] [Related]
57. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly.
Hanew K; Utsumi A; Sugawara A; Shimizu Y; Abe K
J Clin Endocrinol Metab; 1994 Mar; 78(3):509-12. PubMed ID: 8126120
[TBL] [Abstract][Full Text] [Related]
58. Stimulation of growth hormone by vasoactive intestinal polypeptide in acromegaly.
Chihara K; Kaji H; Minamitani N; Kodama H; Kita T; Goto B; Chiba T; Coy DH; Fujita T
J Clin Endocrinol Metab; 1984 Jan; 58(1):81-6. PubMed ID: 6417157
[TBL] [Abstract][Full Text] [Related]
59. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
[TBL] [Abstract][Full Text] [Related]
60. Sex difference in human growth hormone (GH) response to intravenous human pancreatic GH-releasing hormone administration in young adults.
Smals AE; Pieters GF; Smals AG; Benraad TJ; Van Laarhoven J; Kloppenborg PW
J Clin Endocrinol Metab; 1986 Feb; 62(2):336-41. PubMed ID: 3079773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
